CD39 Regulation and Functions in T Cells

Implication of CD69 + CD103 + tissue‐resident‐like CD8 + T cells as a potential immunotherapeutic target for cholangiocarcinoma

(2021) Hyung‐Don Kim et al.   LIVER INTERNATIONAL

CD73 sustained cancer-stem-cell traits by promoting SOX9 expression and stability in hepatocellular carcinoma

(2020) Xiao-Lu Ma et al.   Journal of Hematology & Oncology

Control of Metastases via Myeloid CD39 and NK Cell Effector Function

(2020) Juming Yan et al.   Cancer Immunology Research

Tumor-infiltrating CD39+CD8+ T cells determine poor prognosis and immune evasion in clear cell renal cell carcinoma patients

(2020) Yu Qi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The TGF‐b/SOX4 axis and ROS‐driven autophagy co‐mediate CD39 expression in regulatory T‐cells

(2020) Marlene C. Gerner et al.   FASEB JOURNAL

A single‐nucleotide polymorphism in the human ENTPD1 gene encoding CD39 is associated with worsened graft‐ versus ‐host disease in a humanized mouse model

(2020) Sam R Adhikary et al.   IMMUNOLOGY AND CELL BIOLOGY

Transcriptional Activity and Stability of CD39+CD103+CD8+ T Cells in Human High-Grade Endometrial Cancer

(2020) Hagma H. Workel et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Ecto-NTPDase CD39 is a negative checkpoint that inhibits follicular helper cell generation

(2020) Wenqiang Cao et al.   JOURNAL OF CLINICAL INVESTIGATION

The Expression of Adenosine A2B Receptor on Antigen-Presenting Cells Suppresses CD8+ T-cell Responses and Promotes Tumor Growth

(2020) Siqi Chen et al.   Cancer Immunology Research

Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade

(2020) Rui Yang et al.   Journal for ImmunoTherapy of Cancer

IL-6-induced CD39 expression on tumor-infiltrating NK cells predicts poor prognosis in esophageal squamous cell carcinoma

(2020) Yujia Zheng et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Genetically driven CD39 expression shapes human tumor‐infiltrating CD8 + T‐cell functions

(2020) Daniela Gallerano et al.   INTERNATIONAL JOURNAL OF CANCER

CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer

(2020) Qiangda Chen et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

CD39 identifies the CD4+ tumor-specific T cell population in human cancer

(2020) Kim E Kortekaas et al.   Cancer Immunology Research

Inhibition of the Adenosine Pathway to Potentiate Cancer Immunotherapy: Potential for Combinatorial Approaches

(2020) Elizabeth A. Thompson et al.   Annual Review of Medicine

High Expression of CD39 is Associated with Poor Prognosis and Immune Infiltrates in Clear Cell Renal Cell Carcinoma

(2020) Jie Wu et al.   OncoTargets and Therapy

Detection of CD39 and a Highly Glycosylated Isoform of Soluble CD73 in the Plasma of Patients with Cervical Cancer: Correlation with Disease Progression

(2020) Ricardo Muñóz-Godínez et al.   MEDIATORS OF INFLAMMATION

CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy

(2019) Siqi Chen et al.   Nature Communications

Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity

(2019) Abhishek S. Kashyap et al.   Journal for ImmunoTherapy of Cancer

IL-27 confers a protumorigenic activity of regulatory T cells via CD39

(2019) Young-Jun Park et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies

(2019) Ivan Perrot et al.   Cell Reports

The role of NK cells and CD39 in the immunological control of tumor metastases

(2019) Haiyan Zhang et al.   OncoImmunology

Clonal replacement of tumor-specific T cells following PD-1 blockade

(2019) Kathryn E. Yost et al.   NATURE MEDICINE

Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity

(2019) Xian-Yang Li et al.   Cancer Discovery

CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment

(2019) Shi Yong Neo et al.   JOURNAL OF CLINICAL INVESTIGATION

A2AAdenosine Receptor Gene Deletion or Synthetic A2AAntagonist Liberate Tumor-Reactive CD8+T Cells from Tumor-Induced Immunosuppression

(2018) Jorgen Kjaergaard et al.   JOURNAL OF IMMUNOLOGY

Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma

(2018) Janet Retseck et al.   Journal of Translational Medicine

CD39 is upregulated during activation of mouse and human T cells and attenuates the immune response to Listeria monocytogenes

(2018) Friederike Raczkowski et al.   PLoS One

Functional heterogeneity of circulating T regulatory cell subsets in breast cancer patients

(2018) Yekaterina O. Ostapchuk et al.   Breast Cancer

Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors

(2018) Thomas Duhen et al.   Nature Communications

CD73 expression and clinical significance in human metastatic melanoma

(2018) Inês Monteiro et al.   Oncotarget

Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates

(2018) Yannick Simoni et al.   NATURE

Description of CD8+ Regulatory T Lymphocytes and Their Specific Intervention in Graft-versus-Host and Infectious Diseases, Autoimmunity, and Cancer

(2018) Martha R. Vieyra-Lobato et al.   Journal of Immunology Research

CD39+ regulatory T cells accumulate in colon adenocarcinomas and display markers of increased suppressive function

(2018) Filip Ahlmanner et al.   Oncotarget

The P2X7 Receptor in Infection and Inflammation

(2017) Francesco Di Virgilio et al.   IMMUNITY

The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets

(2017) Bertrand Allard et al.   IMMUNOLOGICAL REVIEWS

Disruption of the ATP/adenosine balance in CD39−/− mice is associated with handling-induced seizures

(2017) Amanda J. Lanser et al.   IMMUNOLOGY

Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses

(2016) Arabella Young et al.   CANCER CELL

Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis

(2016) D. Mittal et al.   CANCER RESEARCH

IL-12 and IL-4 activate a CD39-dependent intrinsic peripheral tolerance mechanism in CD8+T cells

(2016) Alistair Noble et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Expansion of activated regulatory T cells inversely correlates with clinical severity in septic neonates

(2016) Eleonora Timperi et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Overexpression of CD39 in hepatocellular carcinoma is an independent indicator of poor outcome after radical resection

(2016) Xiao-Yan Cai et al.   MEDICINE

Extracellular purines, purinergic receptors and tumor growth

(2016) F Di Virgilio et al.   ONCOGENE

High expression of CD39 in gastric cancer reduces patient outcome following radical resection

(2016) Xiao-Yan Cai et al.   Oncology Letters

CD73 is associated with poor prognosis in HNSCC

(2016) Zhen-Hu Ren et al.   Oncotarget

Expression of CD39 on Activated T Cells Impairs their Survival in Older Individuals

(2016) Fengqin Fang et al.   Cell Reports

Regulatory T cells with multiple suppressive and potentially pro-tumor activities accumulate in human colorectal cancer

(2016) Eleonora Timperi et al.   OncoImmunology

Targeting CD73 in the tumor microenvironment with MEDI9447

(2016) Carl M. Hay et al.   OncoImmunology

Purinergic signaling in the immune system

(2015) Francesco Di Virgilio et al.   AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

The Genetic Architecture of the Human Immune System: A Bioresource for Autoimmunity and Disease Pathogenesis

(2015) Mario Roederer et al.   CELL

CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer

(2015) Marian S. Wettstein et al.   DISEASE MARKERS

The expression of CD39 on regulatory T cells is genetically driven and further upregulated at sites of inflammation

(2015) Anne Rissiek et al.   JOURNAL OF AUTOIMMUNITY

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

CD39 Expression Identifies Terminally Exhausted CD8+ T Cells

(2015) Prakash K. Gupta et al.   PLoS Pathogens

Genetic analysis of an allergic rhinitis cohort reveals an intercellular epistasis between FAM134B and CD39

(2014) Rossella Melchiotti et al.   BMC Medical Genetics

Adenosine A2A Receptors Intrinsically Regulate CD8+ T Cells in the Tumor Microenvironment

(2014) C. Cekic et al.   CANCER RESEARCH

Human OX40 tunes the function of regulatory T cells in tumor and nontumor areas of hepatitis C virus-infected liver tissue

(2014) Silvia Piconese et al.   HEPATOLOGY

Human monocytes respond to extracellular cAMP through A2A and A2B adenosine receptors

(2014) Ester Sciaraffia et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity

(2014) J. Bastid et al.   Cancer Immunology Research

CD39 is highly involved in mediating the suppression activity of tumor-infiltrating CD8+ T regulatory lymphocytes

(2013) Alessia Parodi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Genetic Variants Regulating Immune Cell Levels in Health and Disease

(2013) Valeria Orrù et al.   CELL

Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs

(2013) B. Allard et al.   CLINICAL CANCER RESEARCH

Tumor-Infiltrating Lymphocytes Expressing the Tissue Resident Memory Marker CD103 Are Associated with Increased Survival in High-Grade Serous Ovarian Cancer

(2013) J. R. Webb et al.   CLINICAL CANCER RESEARCH

Association of circulating regulatory T cell number with the incidence and prognosis of diffuse large B-cell lymphoma

(2013) Magdalena Głowala-Kosińska et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

CD73-Deficient Mice Are Resistant to Carcinogenesis

(2012) J. Stagg et al.   CANCER RESEARCH

Phenotypic and functional characteristics of CD4+CD39+ FOXP3+ and CD4+CD39+FOXP3neg T-cell subsets in cancer patients

(2012) Patrick J. Schuler et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Disordered purinergic signaling and abnormal cellular metabolism are associated with development of liver cancer inCd39/Entpd1null Mice

(2012) Xiaofeng Sun et al.   HEPATOLOGY

Stat3 and Gfi-1 Transcription Factors Control Th17 Cell Immunosuppressive Activity via the Regulation of Ectonucleotidase Expression

(2012) Fanny Chalmin et al.   IMMUNITY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity

(2011) Sebastian F. M. Häusler et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis

(2011) J. Stagg et al.   CANCER RESEARCH

Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1

(2011) Eric V. Dang et al.   CELL

Inhibition of T-Cell Proliferation by Murine Multipotent Mesenchymal Stromal Cells is Mediated by CD39 Expression and Adenosine Generation

(2011) Christine Sattler et al.   CELL TRANSPLANTATION

Altered purinergic signaling in CD73-deficient mice inhibits tumor progression

(2011) Gennady G. Yegutkin et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice

(2011) Long Wang et al.   JOURNAL OF CLINICAL INVESTIGATION

ATP Inhibits the Generation and Function of Regulatory T Cells Through the Activation of Purinergic P2X Receptors

(2011) U. Schenk et al.   Science Signaling

CD39/Adenosine Pathway Is Involved in AIDS Progression

(2011) Maria Nikolova et al.   PLoS Pathogens

CD73 on Tumor Cells Impairs Antitumor T-Cell Responses: A Novel Mechanism of Tumor-Induced Immune Suppression

(2010) D. Jin et al.   CANCER RESEARCH

CD39/ENTPD1 Expression by CD4+Foxp3+ Regulatory T Cells Promotes Hepatic Metastatic Tumor Growth in Mice

(2010) Xiaofeng Sun et al.   GASTROENTEROLOGY

cAMP/CREB-mediated Transcriptional Regulation of Ectonucleoside Triphosphate Diphosphohydrolase 1 (CD39) Expression

(2010) Hui Liao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

IL-35 Stimulation of CD39+ Regulatory T Cells Confers Protection against Collagen II-Induced Arthritis via the Production of IL-10

(2010) I. Kochetkova et al.   JOURNAL OF IMMUNOLOGY

Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis

(2010) J. Stagg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Increased Ectonucleotidase Expression and Activity in Regulatory T Cells of Patients with Head and Neck Cancer

(2009) M. Mandapathil et al.   CLINICAL CANCER RESEARCH

CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease

(2009) D. J. Friedman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Deletion of Cd39/Entpd1 Results in Hepatic Insulin Resistance

(2008) K. Enjyoji et al.   DIABETES